Cyprus Sees a Surge In Tourism Revenue: February’s Significant Gains And What It Means

by News Editor

April 29, 2025

In February 2025, Cyprus reported a notable €79.7 million in tourism revenue, reflecting a remarkable 22.4% increase from the same period last year when earnings stood at €65.1 million, according to the latest release by the statistical service.

Year-to-Date Performance

Taking a broader view, the combined revenue for the first two months of 2025 reached €148.9 million, soaring by 35% compared to €110.3 million during the same months in 2024.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Spending Patterns of Tourists

The per capita expenditure for February rose by 14.3%, amounting to €595.71 compared to €521.01 in February 2024. Among the tourists, British visitors, accounting for 24.8% of the arrivals, spent an average of €73.42 per day. Polish tourists made up 15.1% of the total arrivals and spent €71.07 daily. Intriguingly, visitors from Israel had the highest daily spending at €203.06.

Future Prospects

Looking ahead, Harris Papacharalambous, President of Cyprus Travel and Tourism Agents Association, anticipates that a total of 4.25 million tourists will visit Cyprus by the end of the year. The vision for 2026 is to enhance the island’s tourism offerings with innovative changes, turning it into a regional hub for tourism activities, thanks to Cyprus’ strategic geographical position.

For further exploration of Cyprus’s rapid growth and economic potential, read about Cyprus’s fastest-growing tech companies and their global impact.

The Future Forbes Realty Global Properties

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

by News Editor

September 3, 2026

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Breaking news